Nuveen LLC acquired a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 507,527 shares of the company's stock, valued at approximately $807,000. Nuveen LLC owned 0.71% of Zentalis Pharmaceuticals at the end of the most recent quarter.
A number of other hedge funds have also recently modified their holdings of the company. Invesco Ltd. increased its position in shares of Zentalis Pharmaceuticals by 193.8% in the first quarter. Invesco Ltd. now owns 149,484 shares of the company's stock valued at $238,000 after acquiring an additional 98,612 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Zentalis Pharmaceuticals by 4.7% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 361,236 shares of the company's stock valued at $574,000 after acquiring an additional 16,197 shares during the period. GSA Capital Partners LLP increased its position in shares of Zentalis Pharmaceuticals by 275.9% in the first quarter. GSA Capital Partners LLP now owns 541,975 shares of the company's stock valued at $862,000 after acquiring an additional 397,805 shares during the period. Federated Hermes Inc. increased its position in shares of Zentalis Pharmaceuticals by 52.3% in the first quarter. Federated Hermes Inc. now owns 752,517 shares of the company's stock valued at $1,197,000 after acquiring an additional 258,535 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Zentalis Pharmaceuticals in the first quarter valued at about $81,000.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on ZNTL shares. Wall Street Zen upgraded shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 9th. Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Thursday, August 7th. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, August 7th. Finally, Wedbush reiterated a "neutral" rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $8.20.
View Our Latest Stock Analysis on Zentalis Pharmaceuticals
Zentalis Pharmaceuticals Price Performance
NASDAQ:ZNTL traded down $0.02 during mid-day trading on Friday, hitting $1.75. 422,761 shares of the company's stock were exchanged, compared to its average volume of 812,105. Zentalis Pharmaceuticals, Inc. has a one year low of $1.01 and a one year high of $5.44. The business has a fifty day moving average price of $1.49 and a 200 day moving average price of $1.49. The company has a market cap of $126.24 million, a PE ratio of -0.77 and a beta of 1.76.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.19. On average, equities analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.
Zentalis Pharmaceuticals Profile
(
Free Report)
Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.
Further Reading
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
